Predictive Oncology (NASDAQ: POAI) is focused on the use of data and artificial intelligence (AI) to develop personalized cancer therapies, which can lead to more effective treatments and improved patient outcome. The company has several tools that support its mission of bringing precision medicine to the diagnosis of cancer.
Through its subsidiaries, Predictive Oncology’s portfolio of assets includes the following:
- A database of clinically validated historical and outcome data from patient tumors
- An in-house Clinical Laboratory Improvement Amendments (CLIA)-certified lab
- A “smart” patient-derived tumor profiling platform
- An in-house bioinformatics artificial intelligence (AI) platform
- A new computerized approach growing tumors in the lab to rapidly develop patient specific treatment options
- An FDA-approved fluid collection and disposal system
Using these resources, and in collaboration with key players in the pharmaceutical, diagnostic and biotech industries Predictive Oncology is working to determine the best pathways for more individualized and effective cancer treatment.
Through its subsidiaries, Predictive Oncology’s portfolio of assets includes the following:
- A database of clinically validated historical and outcome data from patient tumors
- An in-house Clinical Laboratory Improvement Amendments (CLIA)-certified lab
- A “smart” patient-derived tumor profiling platform
- An in-house bioinformatics artificial intelligence (AI) platform
- A new computerized approach growing tumors in the lab to rapidly develop patient specific treatment options
- An FDA-approved fluid collection and disposal system
Using these resources, and in collaboration with key players in the pharmaceutical, diagnostic and biotech industries Predictive Oncology is working to determine the best pathways for more individualized and effective cancer treatment.
Location: United States, Minnesota, Eagan
Employees: 11-50
Phone: +1 651-389-4806
Founded date: 2002
Mentions in press and media 9
| Date | Title | Description |
| 30.06.2023 | Recent Digital Health Hires & Board Appointments | Theralink Technologies, Inc. appoints Faith Zaslavsky as its new Chief Executive Officer. Ms. Zaslavsky, who has served as the Company’s President and Chief Operating Officer since December 2022, will assume this role effective June 26, 202... |
| 18.04.2023 | Predictive Oncology Adjourns Special Meeting of Stockholders | Predictive Oncology, a science-driven company leveraging its proprietary artificial intelligence and machine learning capabilities, extensive biorepository of tumor samples, Clinical Laboratory Improvement Amendments (CLIA) laboratory and G... |
| 31.03.2023 | Predictive Oncology Announces Collaboration with Integra Therapeutics to Advance Gene Therapy | Predictive Oncology , a science-driven company on the leading edge of oncology drug discovery and development, announces it is partnering with Integra Therapeutics, a company focused on engineering the next generation of gene writing tools ... |
| 19.03.2023 | Weekly AiThority Roundup: Biggest Machine Learning, Robotic And Automation Updates – March 3rd Week | This is your AI Weekly Roundup . We are covering the top updates from around the world. The updates will feature state-of-the-art capabilities in artificial intelligence (AI), Machine Learning, Robotic Process Automation, Fintech, and human... |
| 15.03.2023 | Predictive Oncology Engages LifeSci Advisors as Strategic Investor Relations Partner | Comprehensive, multi-faceted IR program to focus on raising awareness of Predictive Oncology and its portfolio of unique, proprietary assets capable of accelerating oncologic drug discovery and enabling drug development Predictive Oncology,... |
| 26.02.2023 | Predictive Oncology And Cvergenx Announce Partnership To Develop The First-ever Genomics-based Approach Using Artificial Intelligence | Predictive Oncology and Cvergenx, announced an agreement to form a strategic partnership that has the potential to revolutionize the field of radiation oncology with the first-ever genomics-based artificial intelligence approach to personal... |
| 19.12.2022 | Identifying The Value Of Predictive Oncology Inc.’s Oncology Biobank In this Global Drug Discovery Market | Identifying The Value Of Predictive Oncology Inc.’s Oncology Biobank In this Global Drug Discovery Market Predictive Oncology Inc. (NASDAQ:POAI)ATLANTA, GA, US, December 19, 2022 /EINPresswire.com/ -- The global drug discovery market is sig... |
| 12.10.2022 | Predictive Oncology Addresses Gap in Bringing Cancer Drugs to Market | Predictive Oncology Addresses Gap in Bringing Cancer Drugs to Market Predictive Oncology (NASDAQ:POAI)ATLANTA, GEORGIA, UNITED STATES, October 12, 2022 /EINPresswire.com/ -- It can take 12-15 years to bring a drug to market. And less than 8... |
| 06.12.2021 | Predictive Oncology Acquires zPREDICTA, Inc. | Predictive Oncology, (POAI), a knowledge-driven company focused on applying artificial intelligence (AI) to develop personalized cancer therapies, announced the acquisition of zPREDICTA, a company pioneering tumor-specific in vitro 3D cell ... |